<DOC>
	<DOCNO>NCT02992483</DOCNO>
	<brief_summary>The purpose first human study ass safety , tolerability , PK preliminary clinical activity estimate MTD ( ) /RDE ( ) MIK665 ( also refer S64315 ) single agent administer intravenously ( i.v . ) adult patient refractory relapse lymphoma multiple myeloma .</brief_summary>
	<brief_title>Phase I Study MIK665 , Mcl-1 Inhibitor , Patients With Refractory Relapsed Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>The design phase I , open label , dose find study choose order characterize safety tolerability MIK665 determine Maximal Tolerated Dose ( ) ( MTD ( ) ) and/or Recommended Dose ( ) Expansion ( RDE ( ) ) . This study utilize Bayesian Hierarchical model guide dose escalation estimate MTD ( ) base dose-DLT relationship ( ) MIK665 indication . The expansion part study employ open-label multiple arm design . The purpose expansion part ass safety , tolerability , PK , PD anti-tumor activity MIK665 select RDE/s Multiple Myeloma ( MM ) MYC positive Diffuse large B-Cell Lymphoma ( DLBCL ) identify dose-escalation part .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Inclusion Criteria Age â‰¥ 18 year . Histologically confirm lymphoma ( WHO classification ) , confirm MM ( IMWG ) , relapse and/or refractory . Other Inclusion Criteria May Apply . Exclusion Criteria Known history chronic liver disease History chronic pancreatitis . Prior treatment Mcl1 inhibitor . Other Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>dlbcl</keyword>
</DOC>